We work at the intersection of pioneering science and patient need. Our research and development teams seek to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer. Our product candidates leverage the body’s natural pathways, providing us with the scientific insight to investigate their potential across multiple diseases.
Roxadustat, our most advanced therapeutic, is an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, the enzyme that regulates HIF activity. By transiently inhibiting the enzyme, roxadustat induces the body’s natural coordinated process of producing red blood cells, increasing iron absorption, mobilization, and transport. We are developing roxadustat in partnership with AstraZeneca and Astellas for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. With Phase 3 clinical development well underway worldwide, roxadustat is approaching new drug application (NDA) and marketing authorization application (MAA) submissions for use in anemia associated with CKD in multiple markets. Clinical evaluation of roxadustat is expanding into oncology indications as we initiate a China Phase 2/3 trial and a global Phase 3 trial for treatment of anemia associated with myelodysplastic syndromes (MDS).
Pamrevlumab is a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF). CTGF is a common factor in chronic fibrotic and proliferative disorders, characterized by persistent and excessive fibrous tissue which can lead to organ dysfunction and failure, and in cancer, by promotion of tumor growth. Pamrevlumab is in Phase 2 clinical evaluation for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD).